The statistical and study design will be overseen by Dr. Booil Jo, a biostatistician at Stanford University. She is an expert in mixed model regression and experimental design of clinical trials, especially the handling of missing data. To examine the primary hypothesis concerning changes in the ASWS, we will analyze the longitudinal data from the baseline, during treatment, and end of treatment using a method widely known as mixed effects modeling or multilevel analysis. This strategy for modeling longitudinal data is known for better interpretability and to be more efficient than the univariate analytic methods such as ANOVA in terms of handling missing data. Specifically, we will use maximum likelihood estimation method, assuming that data are missing at random and conditional on observed information. This assumption is reasonable given that reasons for attrition will be well monitored in our study. We will model the growth process for sleep to see if there is a significant change. For maximum likelihood estimation of mixed effects models, we will use a latent variable modeling software. Exploratory correlational hypotheses will be tested by first plotting data and determining best fit linear model (fitting with the Kolmogorov-Smirnov algorithm and fit comparisons with Akaike's Information Criterion).
Given the nature of a feasibility study within the R21 framework, we will take into account both statistical significance (p-value) and clinical significance (effect size) in our inference, with more emphasis on the latter. Nonetheless, we calculated the sample size based on the primary outcome measure of the "falling asleep" dimension of the ASWS assuming that the magnitude of the treatment effect would be large. That is, we expect to detect a difference of 0.96 units (large clinical effect size, Cohen's d=0.80). Given that we do not have the detailed information necessary to conduct power calculations for mixed effects modeling, power was estimated based on simple mean comparison at post-treatment follow up assessment. We expect that the power will increase somewhat as we actually analyze the data using the mixed effects modeling by utilizing repeated measures and by properly handling missing data. We use the nominal 5% significance level (two-tailed). Based on this scenario, with 60 subjects (30 control, 30 treatment), estimated power is 0.86, which goes down to 0.73 if adjusted for the multiple outcomes we compare in Hypotheses 1 and 2 ( = 0.05/3 = 0.016).
